Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors

被引:64
作者
Legraverend, M
Ludwig, O
Bisagni, E
Leclerc, S
Meijer, L
Giocanti, N
Sadri, R
Favaudon, V
机构
[1] Ctr Univ Orsay, UMR 176, CNRS, Inst Curie Rech, F-91405 Orsay, France
[2] CNRS, Biol Stn, UPR 9042, Grp Cycle Cellulaire, F-29682 Roscoff, France
[3] Ctr Univ Orsay, INSERM, U350, Inst Curie Rech, F-91405 Orsay, France
关键词
purines; olomoucine; cyclin-dependent kinases; cell cycle; proliferation; human cells;
D O I
10.1016/S0968-0896(99)00064-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Novel C-2, C-6, N-9 trisubstituted purines derived from the olomoucine/roscovitine lead structure were synthesized and evaluated for their ability to inhibit starfish oocyte CDK1/cyclin B, neuronal CDK5/p35 and erk1 kinases in purified extracts. Structure-activity relationship studies showed that increased steric bulk at N-9 reduces the inhibitory potential whereas substitution of the aminoethanol C-2 side chain by various groups of different size (methyl, propyl, butyl, phenyl, benzyl) only slightly decreases the activity when compared to (R)-roscovitine. Optimal inhibitory activity against CDK5, CDK1 and CDK2, with IC50 values of 0.16, 0.45 and 0.65 mu M, respectively, was obtained with compound 21 containing a (2R)-pyrrolidin-2-yl-methanol substituent at the C-2 and a 3-iodobenzylamino group at the C-6 of the purine. Compound 21 proved cytotoxic against human tumor HeLa cells (LD50 = 6.7 mu M versus 42.7 mu M for olomoucine, 24-h contact). Furthermore, unlike olomoucine, compound 21 was effective upon short exposure (LD50 = 25.3 mu M, 2-h contact). The available data suggest that the affinity for CDKs and the cytotoxic potential of the drugs are inter-related. However, no straightforward cell cycle phase specificity of the cytotoxic response to 21 was observed in synchronized HeLa cells. With the noticeable exception of pronounced lengthening of the S-phase transit by 21 applied during early-S in synchronized HeLa cells, and in striking contrast with earlier reports on studies using plant or echinoderm cells, olomoucine and compound 21 were unable to reversibly arrest cell cycle progression in asynchronous growing HeLa cells. Some irreversible block in G1 and G2 phase occurred at high olomoucine concentration, correlated with induced cell death. Moreover, chronic exposure to lethal doses of compound 21 resulted in massive nuclear fragmentation, evocative of mitotic catastrophe with minor amounts of apoptosis only. It was also found that olomoucine and compound 21 reversibly block the intracellular uptake of nucleosides with high efficiency. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1281 / 1293
页数:13
相关论文
共 55 条
[1]   CELLULAR EFFECTS OF OLOMOUCINE, AN INHIBITOR OF CYCLIN-DEPENDENT KINASES [J].
ABRAHAM, RT ;
ACQUARONE, M ;
ANDERSEN, A ;
ASENSI, A ;
BELLE, R ;
BERGER, F ;
BERGOUNIOUX, C ;
BRUNN, G ;
BUQUETFAGOT, C ;
FAGOT, D ;
GLAB, N ;
GOUDEAU, H ;
GOUDEAU, M ;
GUERRIER, P ;
HOUGHTON, P ;
HENDRIKS, H ;
KLOAREG, B ;
LIPPAI, M ;
MARIE, D ;
MARO, B ;
MEIJER, L ;
MESTER, J ;
MULNERLORILLON, O ;
POULET, SA ;
SCHIERENBERG, E ;
SCHUTTE, B ;
VAULOT, D ;
VERLHAC, MH .
BIOLOGY OF THE CELL, 1995, 83 (2-3) :105-120
[2]   COMPUTER-PROGRAMS FOR THE ANALYSIS OF CELLULAR-SURVIVAL DATA [J].
ALBRIGHT, N .
RADIATION RESEARCH, 1987, 112 (02) :331-340
[3]  
AZZI L, 1994, J BIOL CHEM, V269, P13279
[4]  
BARTKOVA J, 1997, PROGR CELL CYCLE RES, P211
[5]  
BOUMCHITA H, 1991, HETEROCYCLES, V32, P1785
[6]   Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication [J].
Bresnahan, WA ;
Boldogh, I ;
Chi, P ;
Thompson, EA ;
Albrecht, T .
VIROLOGY, 1997, 231 (02) :239-247
[7]   CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation [J].
Brooks, EE ;
Gray, NS ;
Joly, A ;
Kerwar, SS ;
Lum, R ;
Mackman, RL ;
Norman, TC ;
Rosete, J ;
Rowe, M ;
Schow, SR ;
Schultz, PG ;
Wang, XB ;
Wick, MM ;
Shiffman, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (46) :29207-29211
[8]  
Brüsselbach S, 1998, INT J CANCER, V77, P146
[9]   Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines [J].
BuquetFagot, C ;
Lallemand, F ;
Montagne, MN ;
Mester, J .
ANTI-CANCER DRUGS, 1997, 8 (06) :623-631
[10]   REVERSAL OF TERMINAL DIFFERENTIATION AND CONTROL OF DNA-REPLICATION - CYCLIN-A AND CDK2 SPECIFICALLY LOCALIZE AT SUBNUCLEAR SITES OF DNA-REPLICATION [J].
CARDOSO, MC ;
LEONHARDT, H ;
NADALGINARD, B .
CELL, 1993, 74 (06) :979-992